Eli Lilly says obesity pill helps maintain weight loss
Digest more
Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...
The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...
Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...
Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...
A federal judge allowed some of Eli Lilly & Co.‘s claims to proceed that allege a Texas-based compounding pharmacy violated ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...
Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback